Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus GG + peanut oral immunotherapy
- Development stage
- Unknown
- Lead developer
- Prota Therapeutics
- Modality
- Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus GG + peanut oral immunotherapy, also known as PPOIT (probiotic and peanut oral immunotherapy), is a combination immunotherapy developed by the Murdoch Children's Research Institute (MCRI) for the treatment of peanut allergy in children. [6, 8] The therapy consists of the daily oral administration of the probiotic *Lactobacillus rhamnosus* GG (strain CGMCC 1.3724/ATCC 53103) combined with peanut oral immunotherapy (OIT). [10, 13, 17] The treatment is designed to modulate the immune system's allergic response to peanuts, aiming to induce long-term, sustained unresponsiveness (remission) rather than just temporary desensitization. [2, 5, 7] This immunomodulatory effect involves reducing peanut-specific IgE levels and rewiring T-helper 2 (Th2) gene networks associated with the allergic response. [2, 4] The technology has been licensed to Prota Therapeutics, which is developing a high-dose version as PRT120 and preparing for Phase 3 trials. [3, 9, 20]
- Other names
- PPOITprobiotic and peanut oral immunotherapy
Beyond the preview
Go deeper on lactobacillus rhamnosus GG + peanut oral immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus GG + peanut oral immunotherapy.